Ocugen (NASDAQ: OCGN) director awarded 170,100 stock options at $1.22 strike

Rhea-AI Filing Summary

Ocugen, Inc. director Kirsten Castillo received a grant of stock options as equity compensation. The award covers 170,100 options to buy common stock at an exercise price of $1.22 per share, expiring on June 11, 2036.

The options vest upon the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders, provided she continues to serve through the vesting date. Following this grant, she holds 170,100 derivative securities related to common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Castillo Kirsten

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	170,100	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 170,100 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 170,100 options Exercise price: $1.22 per share Expiration date: June 11, 2036 +3 more

6 metrics

Options granted 170,100 options Stock Option (Right to Buy) grant

Exercise price $1.22 per share Stock option strike price

Expiration date June 11, 2036 Option expiration

Underlying shares 170,100 shares Common stock underlying options

Post-transaction derivative holdings 170,100 options Total derivative securities following transaction

Vesting date trigger June 11, 2027 Latest vesting date if no earlier annual meeting

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, annual meeting of stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 1.2200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-11T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual meeting of stockholders financial

"Ocugen, Inc.'s next annual meeting of stockholders"

vesting financial

"The option vests upon the earlier of (a) June 11, 2027 or (b) Ocugen, Inc.'s next annual meeting of stockholders"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Castillo Kirsten

(Last) (First) (Middle)

C/O OCUGEN, INC.

11 GREAT VALLEY PARKWAY

(Street)

MALVERN PENNSYLVANIA 19355

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ocugen, Inc. [ OCGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.22	06/11/2026		A		170,100		(1)	06/11/2036	Common Stock	170,100	$0	170,100	D

Explanation of Responses:

1. The option vests upon the earlier of (a) June 11, 2027 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Shankar Musunuri, attorney-in-fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Ocugen (OCGN) director Kirsten Castillo report in this Form 4?

She reported receiving a grant of 170,100 stock options tied to Ocugen common stock. These options are a form of equity compensation and were awarded at an exercise price of $1.22 per share, with a long-dated expiration in 2036.

What are the key terms of Kirsten Castillo’s stock option grant at Ocugen (OCGN)?

The grant covers 170,100 options with an exercise price of $1.22 per share, expiring on June 11, 2036. The options relate to Ocugen common stock and represent a right to buy shares in the future if the vesting conditions are met.

When do the Ocugen (OCGN) stock options granted to Kirsten Castillo vest?

The options vest on the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders. Vesting is also conditioned on her continued service with the company through the applicable vesting date, as specified in the filing footnote.

How many Ocugen (OCGN) derivative securities does Kirsten Castillo hold after this transaction?

After this grant, she holds 170,100 derivative securities related to Ocugen common stock. This figure reflects the stock options reported in the Form 4 and represents her position following the acquisition transaction disclosed.

Is Kirsten Castillo’s Ocugen (OCGN) transaction a purchase or a compensation grant?

The transaction is a compensation grant, not an open-market purchase. It is coded as a grant or award acquisition, providing stock options at a set exercise price rather than involving immediate cash payment to acquire common shares.